Last reviewed · How we verify
NCT04033302
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Phase 1, PHASE2 trial testing CD7-specific CAR gene-engineered T cells in T-cell Acute Lymphoblastic Leukemia in 30 participants. Status unknown.
31 July 2021
Quick facts
| Lead sponsor | Shenzhen Geno-Immune Medical Institute |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 September 2019 |
| Primary completion | 31 July 2021 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD7-specific CAR gene-engineered T cells — full drug profile →
Conditions studied
- T-cell Acute Lymphoblastic Leukemia — all drugs for T-cell Acute Lymphoblastic Leukemia →
- T-cell Acute Lymphoblastic Lymphoma — all drugs for T-cell Acute Lymphoblastic Lymphoma →
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
- NK Cell Lymphoma — all drugs for NK Cell Lymphoma →
Sponsor
Shenzhen Geno-Immune Medical Institute
Who can join
Adults 6 Months to 75, any sex, with T-cell Acute Lymphoblastic Leukemia or T-cell Acute Lymphoblastic Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cell therapy against CD7-positive hematological malignancies using CD7 specific CAR T cells. The study also aims to learn more about the function of CD7 CAR T cells and their persistence in patients of hematological malignancies.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T, Greil R, Zaborsky N, Geisberger R. · · 2021 · cited 115× · PMID 34445701 · DOI 10.3390/ijms22168996 -
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.
Fleischer LC, Spencer HT, Raikar SS. · · 2019 · cited 95× · PMID 31884955 · DOI 10.1186/s13045-019-0801-y -
CAR-T cell therapy for cancer: current challenges and future directions.
Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, et al · · 2025 · cited 81× · PMID 40610404 · DOI 10.1038/s41392-025-02269-w -
CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. · · 2021 · cited 56× · PMID 34620233 · DOI 10.1186/s13287-021-02595-0 -
Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia.
Pastorczak A, Domka K, Fidyt K, Poprzeczko M, et al · · 2021 · cited 42× · PMID 33810515 · DOI 10.3390/cancers13071536 -
Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.
Bayón-Calderón F, Toribio ML, González-García S. · · 2020 · cited 42× · PMID 33081391 · DOI 10.3390/ijms21207685 -
Immunotherapy of lymphomas.
Ansell SM, Lin Y. · · 2020 · cited 37× · PMID 32039913 · DOI 10.1172/jci129206 -
Biomarkers as targets for CAR-T/NK cell therapy in AML.
Shao R, Li Z, Xin H, Jiang S, et al · · 2023 · cited 32× · PMID 37330575 · DOI 10.1186/s40364-023-00501-9
Verify or expand the search:
- PubMed search for NCT04033302
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for T-cell Acute Lymphoblastic Leukemia
Currently open trials in the same condition.
- NCT06561074 — A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Ad · Phase 2 · recruiting
- NCT06514794 — A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lym · Phase 2 · recruiting
- NCT06686108 — Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relap · Phase 2 · recruiting
- NCT06420076 — Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using · Phase 1, PHASE2 · recruiting
- NCT06316427 — Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies · Phase 1, PHASE2 · recruiting
Other Shenzhen Geno-Immune Medical Institute trials
Trials by the same sponsor.
- NCT07501156 — H3K27M-specific Immune Effector Cells Targeting DMG/DIPG · Phase 1, PHASE2 · recruiting
- NCT07495956 — cfMSC Therapy for Diabetes · Phase 1, PHASE2 · recruiting
- NCT07477600 — cfMSC Stem Cell Therapy Targeting COPD · Phase 1, PHASE2 · recruiting
- NCT07180927 — DLL3 CAR-T Therapy Targeting Brain Tumors · Phase 1, PHASE2 · recruiting
- NCT07193966 — NG2 and DLL3 CAR-T Cells Targeting Melanoma · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04033302 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Geno-Immune Medical Institute
- Last refreshed: 19 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04033302.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing